Abstract:Background: Traditional Chinese medicine injection for Activating Blood Circulation (TCMi-ABC), which exhibits comparable anticoagulant and antiplatelet effects, is commonly used as an adjuvant treatment for acute myocardial infarction (AMI) in China. Objective: The aim of this study was to conduct a meta-analysis to assess the efficacy and safety of TCMi-ABC in combination with conventional western medicine in reducing mortality associated with AMI. Methods: We conducted a comprehensive search of PubMed, Cochrane Library, EMBASE, Web of Science, CBM, WanFang Data, and CNKI databases. Randomized controlled trials (RCTs) investigating the use of TCMi-ABC (including Danhong injection, sodium tanshinone IIA sulfonate injection, salvia miltiorrhiza ligupyrazine injection, and puerarin injection) for the treatment of AMI were included. The search included studies published from the inception of the databases up to December 2022. Two authors independently screened RCTs, extracted data, and assessed the risk of bias. Meta-analysis was performed using RevMan 5.3 and Stata 17.0. The quality of evidence was evaluated using the GRADE approach. Results: A total of 52 RCTs involving 5363 patients were included in the analysis, none of which described independent testing of the purity or potency of the TCMi-ABC product used. 19/52 reported random sequence generation. All RCTs lack adequate description of allocation concealment. 51/52 failed to assess blinding. The meta-analysis results demonstrated that the combined application of TCMi-ABC, compared with conventional western medicine treatment alone, significantly reduced in-hospital mortality in AMI patients [RR= 0.41, 95% CI (0.29, 0.59), P < 0.05], decreased the incidence of malignant arrhythmia [RR= 0.40, 95% CI (0.26, 0.61), P < 0.05], and increased left ventricular ejection fraction (LVEF) [MD= 5.53, 95% CI (3.81, 7.26), P < 0.05]. There was no significant difference in the incidence of adverse events between the two groups (P > 0.05). The GRADE evidence quality classification indicated that the evidence for in-hospital mortality, malignant arrhythmia, and adverse events was of moderate quality, while the evidence for LVEF was of low quality. Conclusion: TCMi-ABC demonstrates additional clinical value in reducing mortality and the risk of malignant arrhythmia in patients with AMI. However, further validation of these findings is warranted through high-quality clinical trials due to methodological weaknesses in randomization, blinding, allocation concealment, and insufficient assessing for the purity/potency of herbs and the gram amount of active constituents. Systematic review registration: [INPLASY], identifier [INPLASY202170082].

Effect of Administration of Safflower Yellow Injection on the Platelet Aggregate Rate and Transforming Growth Factor-Β_1 in Patients Without ST Elevation Acute Myocardial Infarciton

Curative effect of safflower injection on non-ST elevation acute coronary syndrome and protective effect on interventional therapy

To Compare the Curative Effect of the Antiplatelet Therapy Between Puerarin Injection and Xueshuantong Injection Among Patients with Unstable Angina After Percutaneous Coronary Stent Implantation

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

Effect of Safflower Yellow Pigment on Blood Rheology and Cerebral Hemodynamics in Patients with Acute Cerebral Infarction

Changes of Platelet Activation Markers and Platelet Ultra-Microstructure in the Patients with Acute Myocardial Infarction

Observation of curative effect of the antiplatelet therapy of danhong injection among patients with acute myocardial infarction after percutaneous coronary stent implantation

Influences of tirofiban hydrochloride on platelet aggregation rate,sCD40L level and prognosis in patients with non-ST-elevation acute coronary syndrome

Effects of tirofiban on non-ST-segment elevation acute myocardial infarction

Safflower Extract Inhibits ADP-Induced Human Platelet Aggregation

Effects of liposomal prostaglandin E1 on fibrinolytic system in peri-percutaneous coronary interventional in acute coronary syndrome

[Effects of Ischemic Reperfusion on the Expression of Cell Adhesion Molecules and Monocyte Chemotactic Protein-1 and the Protective Role of MgSO4].

Safflower Yellow Injection Alleviates Myocardial Ischemia/Reperfusion Injury by Reducing Oxidative and Endoplasmic Reticulum Stress

Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis

Mechanism Repositioning Based on Integrative Pharmacology: Anti-Inflammatory Effect of Safflower in Myocardial Ischemia–Reperfusion Injury

Traditional chinese medicine injections with activating blood circulation, equivalent effect of anticoagulation or antiplatelet, for acute myocardial infarction: A systematic review and meta-analysis of randomized clinical trials

Abstract 12438: Efficacy and Safety Evaluation of a Platelet Glycoprotein Ib Inhibitor for Patients with Non-ST Segment Elevation Myocardial Infarction

Safflower injection inhibits pulmonary arterial remodeling in a monocrotaline-induced pulmonary arterial hypertension rat model

Effects of Shenfu injection on myocardial adenosine receptors in rats with myocardial ischemia-reperfusion postconditioning

Comparison of Inhibitory Effects of Safflower Decoction and Safflower Injection on Protein and mRNA Expressions of iNOS and IL-1 β in LPS-Activated RAW264.7 Cells

The study of effects of combination of puerarin and compound salvia miltiorrhiza on thrombogenic and fibrinolytic activities in patients with unstable angina pectoris